Serum anti-myomeglin antibodies is a useful tumor marker to detect gastrointestinal cancer

为了寻找新的食管鳞状细胞癌（SCC）血清标志物，采用重组cDNA表达克隆技术（SEREX）对抗原进行了血清学鉴定。用食管癌细胞系（T.Tn） mRNA制备的λZAPII噬菌体cDNA文库感染大肠杆菌，筛选iptg诱导的cDNA产物与食管鳞状细胞癌患者同种异体血清抗体的相互作用。我们发现myomegalin（磷酸二酯酶4D相互作用蛋白/PDE4DIP）是食管SCC的一种新的SEREX抗原。Western blotting分析显示，91例患者中有43例（47%）存在血清抗肌大蛋白抗体（s-myomegalin-Abs），而45例健康对照中只有1例（2.2%）存在血清抗肌大蛋白抗体。I期患者中有38%存在抗肌肥大素抗体。s-myomegalin-Abs在其他常规肿瘤标志物中阳性率最高。虽然s-myomegalin-Abs的存在与相关患者的任何临床病理特征无关，但多因素分析表明，s-myomegalin-Abs的存在与良好的预后显著相关

In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E. coli was infected with λZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified myomegalin (phosphodiesterase 4D interacting protein/PDE4DIP) as a new SEREX antigen for esophageal SCC. Western blotting analysis revealed that serum anti-myomegalin antibodies (s-myomegalin-Abs) were present in 43 out of 91 (47%) patients but in only one out of 45 (2.2%) healthy controls. Anti-myomegalin Abs were present 38% of stage I patients. The positive rate of s-myomegalin-Abs was the highest among the other conventional tumor markers. Although the presence of s-myomegalin-Abs was not related to any of clinicopathological features of the patients concerned, multivariate analysis indicated that presence of s-myomegalin-Abs was significantly associated with favorable prognosis